BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Astrazeneca 'Acerta[s]' its ambitions in blood cancer with $4B deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Astrazeneca 'Acerta[s]' its ambitions in blood cancer with $4B deal
Dec. 18, 2015
By
Michael Fitzhugh
No Comments
Astrazeneca plc is buying 55 percent of privately held Acerta Pharma LLC, the developer of acalabrutinib, a phase III oral small-molecule Bruton's tyrosine kinase (BTK) inhibitor that it expects to transform the treatment of B-cell malignancies.
BioWorld